



C Parker

Contact

C Parker

Publications (12)

Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 2019; 30:e3.

Pezaro C, James N, Logothetis C, Morgans A, Parker C, Ryan C, Saad F, Sartor O, Small E, Sternberg C, Sweeney C, Tannock I, Tombal B, Hussain M, Higano C, Omlin A, Mastris K, Attard G, Beer T, Chi K, Chowdhury S, Davis I, Drake C, de Bono J, Efstathiou E, Gravis G, Gillessen Sommer S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. *Ann Oncol* 2017; 28:1692-1694.

Parker C, Gillessen Sommer S, Horwich A. appendix 8: Prostate cancer: eUpdate published online September 2016 (<http://www.esmo.org/Guidelines/Genitourinary-Cancers>). *Ann Oncol* 2016; 27:v146-v147.

Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 2016

Parker C, Gillessen Sommer S, Heidenreich A, Horwich A. Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al. *Ann Oncol* 2016; 27:750-1.

Parker C, Gillessen Sommer S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015; 26 Suppl 5:v69-77.

Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 2015; 26:1589-604.

Pezaro C, Sohaib A, de Bono J, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin A, Tunariu N. Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. *Clin Radiol* 2014

Lorente D, de Bono J, Gillessen Sommer S, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin A, Attard G. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. *Br J Cancer* 2014

Cuzick J, Minasian L, Parker C, Parnes H, Perner S, Rittenhouse H, Schalken J, Schmid H, Schmitz-Dräger B, Schröder F, Stenzl A, Tombal B, Wilt T, Meyskens F, Marberger M, Lilja H, Thorat M, Andriole G, Brawley O, Brown P, Culig Z, Eeles R, Ford L, Hamdy F, Holmberg L, Ilc D, Key T, Vecchia C, Wolk A. Prevention and early detection of prostate cancer. *Lancet Oncol*, 15: 2014:484-92.

Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. Br J Cancer 2013; 110:267-8.

Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br J Cancer 2013; 109:1079-84.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch